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Cutaneous squamous cell carcinoma (cSCC) is the se-
cond most common type of solid human tumour and a 
main cause of cancer-related death in the general popu-
lation (1, 2). Typically, it emerges on ultraviolet (UV)-
exposed sun-damaged skin from benign intraepithelial 
lesions called actinic keratosis (AK) (3, 4). High-risk 
patient groups, such as organ transplant recipients (OTR), 
display a 65–250-fold increase in cSCC, making cSCC 
the most frequent cancer in this group (5). However, not 
all OTR develop cSCC, while some develop a multi-
plicity of sSCC (1). This discrepancy is the major focus 
of the current study.
Specific genetic factors, such as single nucleotide po-
lymorphisms (SNPs) determining cSCC susceptibility in 
OTRs, have been little-studied. Only a few papers have 
addressed this topic (6–8). Moreover, only one group has 
performed genome-wide association studies (GWAS), 
replicating 10 candidate SNPs previously associated with 
skin cancer in the general population; however, they did 
not show SNP-significant genome-wide association with 
cSCC in the OTRs (7). Our GWAS revealed novel OTR-
specific SNP associated with cSCC susceptibility in OTR. 
METHODS AND RESULTS
Patient data and material were collected prospectively from the 
Swiss Transplant Cohort Study (STCS), from adult solid-organ 
transplant recipients who received either kidney, liver, lung, heart, 
pancreas, small bowel or mixed organ transplant between 2008 and 
2011. Skin cancer episodes after or during transplantation were 
reviewed by an independent clinician. All patients had provided 
written informed consent for participation in the STCS (including 
genetic analyses). The protocol was approved by the independent 
ethics committees of each Swiss participating centre (University 
Hospital of Lausanne; University Hospitals of Geneva; University 
Hospital Zürich; Cantonal Hospital St Gallen; Inselspital, Bern 
University Hospital; ClinicaLuganese, Lugano; and University 
Hospital of Basel and registered at ClinicalTrials.gov Identifier 
NCT01204944). To identify susceptibility SNPs for cSCC, GWAS 
were performed on 61 OTR patients with cSCC and 908 skin 
cancer negative-OTR patients. Genome-wide genotyping was 
performed on DNA samples extracted from EDTA blood using 
the Illumina® Human Omni Express chip Genome Studio software 
and default parameters were used to call genotypes. GWAS were 
conducted using frequentist association tests in SNPtest. Asso-
ciations meeting the genome-wide threshold p-values of 5 × 10–8 
were considered statistically significant.
The raw genotype data-set included 719,665 variants. After ex-
clusion, 627,443 remained. The total number of imputed SNPs was 
42,400,475. Exclusion criteria were: violation of Hardy-Weinberg-
principle (p<1E-6), call rate < 0.95, minor allele frequency (MAF) 
< 0.01, and minor allele count (MAC) < 3. Untyped variants were 
imputed using a combined reference panel of the 1,000 Genomes 
Project phase 3 (9) and Genome of the Netherlands v5 (10) total-
ling more than 90 million genetic variants across the genome. 
The software package SHAPEIT (11) was used for phasing and 
IMPUTE2 (12) for imputation. The info statistic was computed 
to establish imputation accuracy and markers with info < 0.7 were 
excluded from further analysis.
For the complex MHC region, imputation of SNPs, multi-allelic 
markers, amino acids, and classical HLA alleles using validated 
SNP2HLA pipelines were performed. Preliminary results in a 
subset of samples with HLA serology data showed that accuracy 
is very high for HLA-A, -B, -DRB1, and DQB1 (> 95%), and high 
for HLA-C (90%) in Europeans.
Manhattan plots were generated using the R package qqman 
(http://biorxiv.org/content/biorxiv/early/2014/05/14/005165.full.
pdf). SNPs were queried against dbSNP (https://www.ncbi.nlm.
nih.gov/projects/SNP/) and the ensembl variation database (http://
www.ensembl.org/info/genome/variation/index.html). The results 
were combined with annotation results obtained with snpEff (13).
GWAS identified 1 SNP, rs34567942, to be significantly as-
sociated with cSCC in OTRs at the p-value threshold of 5×10–8 
(Fig. 1). Table I shows the characteristics of SNP rs345567942; 
namely the alternative nucleotide, imputation accuracy and im-
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Fig. 1. Manhattan plot visualizing genome-wide association of 
61 cutaneous squamous cell carcinoma (cSCC)-organ transplant 
recipients (OTRs) and 908 skin cancer negative-OTRs, showing 
–log10 p-value of SNPtest along chromosomes. Horizontal red line 
represents the significant threshold p-value of 5×10–8. Arrow indicates single 
nucleotide polymorphism rs34567942 with the most prominent p-value.
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putation quality. rs34567942 is a non-protein-coding intergenic 
SNP, located in a non-repetitive DNA region (https://genome-euro.
ucsc.edu) on chromosome 8. 
DISCUSSION
Studies dealing with the specific genetic factors determi-
ning cSCC susceptibility in OTR are scarce. Burger et 
al. performed allele-specific sequencing and revealed 
gene-specific SNPs in OTRs with cSCC (6). However, 
this study could not find significant associations between 
the SNPs and the risk of cSCC development in OTRs. 
Sanders et al. were the first to perform GWAS on OTRs 
with cSCC, even though this study replicates 10 candidate 
SNPs previously associated with skin cancer in the general 
population, it did not show SNP-significant genome-wide 
association with cSCC in the OTRs (7). In our GWAS, 
we have identified one novel non-coding SNP meeting 
the genome-wide significance and previously unrelated to 
cSCC susceptibility in OTR. In addition, the Variant Ef-
fect Predictor (http://grch37.ensembl.org/Homo_sapiens/
Tools/VEP) incorporated LoFtool (Loss-of-Function tool) 
revealed possibly damaging effects of rs34567942 on the 
nearby FBXO25 gene (14). FBXO25 was shown to be 
expressed and mutated in head and neck SCC (http://www.
cbioportal.org/), suggesting possible SNP involvement.
Despite the small sample size, the current study de-
scribes a novel gene variation that could be functionally 
explored for development of safer individualized medica-
tion. Therefore, we will continue to expand the number 
of OTRs in this continuous project.
Bearing in mind that some GWAS hits are not re-
plicated in subsequent populations, the results of this 
study should be considered preliminary until validated 
in a second set of cases and controls. In order to do this, 
we will continue expanding the number of OTRs in this 
continuous project. In conclusion, this study provides 
a novel gene variation that, once confirmed, could be 
functionally explored for development of safer indivi-
dualized medication. 
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Table I. Characteristics of single nucleotide polymorphism (SNP) rs345567942, namely the position of the SNP on the chromosome, 
reference and alternative allele (R/A), minor allele, minor allele frequency (MAF), imputation accuracy (Info) and whether a SNP is 
located in repetitive region of the DNA (RM-repetitive masker)
Locus Position SNP Gene DNA region R/A Minor allele MAF p-value Info RM
Chr 8p23 284283 rs34567942 Upstream of RP1163E5.6, FBXO25, OR4F21 Intergenic C/T T 0.22 2.9×10–8 0.95 NO
